Health Catalyst to present at Wells Fargo healthcare conference

0 min read | Published on 01 Sept 2026, 01:59 AM |Updated on 01 Sept 2026, 01:59 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Health Catalyst management to speak at Wells Fargo conference
Event scheduled for September 9-10, 2026 in Boston
Company cites $2.8 billion in documented outcomes

*this image is generated using AI for illustrative purposes only.

Health Catalyst, Inc. (NASDAQ: HCAT) announced that its senior management team will participate in the 2026 Wells Fargo Healthcare Conference. The event is scheduled to take place in Boston on September 9 and 10, 2026.

The healthcare intelligence company stated it aims to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Health Catalyst leverages proprietary AI-driven technology and deep domain expertise to help health systems move from data to confident action.

Company Overview

Health Catalyst reports having $2.8 billion in documented outcomes. The firm focuses on enabling measurable improvements for health systems through its intelligence platform.

Investor Relations

Investors seeking further information can contact Stephanie St. Clair, Senior Vice President of Finance and Investor Relations, at +1 (855)-309-6800 or via email at ir@healthcatalyst.com .

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might Health Catalyst's presentation at the Wells Fargo Healthcare Conference influence investor sentiment regarding its AI-driven revenue growth projections for 2026?

What specific metrics from the $2.8 billion in documented outcomes are likely to be highlighted to demonstrate ROI for health systems facing margin pressures?

Could the upcoming conference serve as a catalyst for new partnership announcements or strategic acquisitions in the healthcare intelligence sector?

Wells Fargo lowers Health Catalyst price target to $1.5

0 min read | Published on 13 Aug 2026, 08:32 PM |Updated on 13 Aug 2026, 08:32 PM

Reviewed by

Ritika DScanX News Team

Add as a preferred
source on Google

Key Highlights

Wells Fargo analyst Stan Berenshteyn maintains an Equal-Weight rating on Health Catalyst (NASDAQ: HCAT). The price target was lowered from $1.75 to $1.5, reflecting a modest downward revision in valuation expectations.

*this image is generated using AI for illustrative purposes only.

Wells Fargo analyst Stan Berenshteyn maintains an Equal-Weight rating on Health Catalyst (NASDAQ: HCAT) while lowering the price target from $1.75 to $1.5.

The adjustment reflects a revised valuation outlook for the healthcare technology company, though the neutral stance indicates no immediate recommendation for over- or under-weighting in portfolios.

Analyst Action

Wells Fargo reduced the price target by $0.25, citing updated market conditions or internal modeling adjustments specific to Health Catalyst’s trajectory. The Equal-Weight rating remains unchanged, suggesting the stock is fairly valued relative to its peers at current levels.

Metric	Previous	Current
Price Target	$1.75	$1.5
Rating	Equal-Weight	Equal-Weight

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific changes in Health Catalyst's internal modeling or market conditions prompted Wells Fargo to lower the price target while maintaining an Equal-Weight rating?

How does the new $1.50 price target compare to current consensus estimates from other major Wall Street analysts covering HCAT?

Could this valuation adjustment signal broader headwinds for healthcare technology firms, or is it isolated to Health Catalyst's specific growth trajectory?